Menu
Essilor is a global leader in the ophthalmic optics market, with a market cap of around $64 billion. The company designs, manufactures and markets lenses to correct or protect eyesight and is the world’s largest manufacturer of ophthalmic lenses. Its activities are largely focused on research and development. Essilor has around 70,000 employees with 32 plants and 14 distribution centers worldwide and a footprint in over 100 countries.
Tobii is the global leader in eye tracking and operates through its three business
units: Tobii Dynavox – makes specially designed computers that are controlled by eye movement for use by people with special needs. Tobii Pro – sells eye-tracking equipment used today by more than 3,500 companies and 2,500 research
institutions. Tobii Tech – develops Tobii’s technology for new volume markets, such as computer games, personal computers, virtual and augmented reality, healthcare and industrial applications.
Founded in 2016, Rimonci firmly focuses on vertical fields and engages in a superbly operated VC mode. Its first fund, “Rimonci Global Vision Science Fund”, centers around visual science including the ophthalmology, optometry and neuro-ophthalmology fields mainly in America, Israel, Europe and Greater China. With the motto “For Better Vision and Insight”, closely integrating healthcare and IT and with an in-depth industrial understanding and abundant operation and management experience, Rimonci follows the philosophy of “Consult, Connect and Conduct” to help drive its portfolio companies to success through the elaborately established industry ecosystem.
Club 100 Plus, a private investors club, enables its members to create diversified investments portfolios tailored to each member’s personal preferences, with relatively small investment amounts and with a high probability of success relative to the risk involved. Operating since 2011, the Club has thus far made over 50 investments. The Club has a collaboration agreement with the world’s largest private investment network, Keiertsu Forum, headquartered in the United States.
EIT Health’s goal is to sustainably advance healthcare and promote future conditions for healthier living and well-being of people across Europe. EIT Health leverages the expertise of >140 leading organizations spanning key areas of healthcare. Chosen by the European Institute of Innovation and Technology (EIT), the consortium offers
best-in-class research capabilities, higher education, and business expertise. With a budget of 2 Billion €, provided in part by Horizon2020, EIT Health invests in Europe’s best entrepreneurial talents and creative minds to foster the development and commercialization of smart products and service solutions in the health sector, thereby addressing the challenges imposed by demographic change and ageing societies.
The Israel Innovation Authority, part of Israel’s Ministry of Economy, is the Israeli government’s support arm, charged with fostering the development of industrial R&D within the State of Israel. The Authority’s operations are facilitated through a variety of international programs, agreements and collaborations. Its mission is to assist the advancement of Israel’s knowledge-based science and technology industries in order to encourage innovation and entrepreneurship while stimulating economic growth. The Innovation Authority has issued 3 grants to NovaSight, totaling $1 million.
The Notal Vision Monitoring Center is a full-service, ophthalmic monitoring center directed by practicing ophthalmologists and supported by a team of certified ophthalmic professionals. The company provides physicians with remote monitoring services to support their patient care between office visits.
As a Medicare credentialed digital healthcare provider, Notal Vision offers comprehensive patient education, training, and monitoring to facilitate a high level of compliance for clinical efficacy, leading to better visual outcomes.
© 2022 NovaSight | All Rights Reserved | NS-00779-R08
CureSight™ and EyeSwift®PRO devices are CE marked in accordance with EU Medical Device Regulation 2017/745.
CureSight™ is an FDA 510(K) cleared device.
Caution: The EyeSwift®PRO system is an Investigational Device, Limited By Federal (Or United States) Law To Investigational Use.
Currently, TrackSightTM is not approved for sales in any country.
Your data will be handled in accordance with our Privacy Policy. In the event that a child’s or minor’s information is being submitted as part of this form, we hereby request that such information be submitted solely by the legal guardian of such child or minor.
This website uses cookies for functional, operational, analytical and advertising purposes. Please review our Privacy Policy for more information
